438 related articles for article (PubMed ID: 19414811)
1. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.
Mandruzzato S; Solito S; Falisi E; Francescato S; Chiarion-Sileni V; Mocellin S; Zanon A; Rossi CR; Nitti D; Bronte V; Zanovello P
J Immunol; 2009 May; 182(10):6562-8. PubMed ID: 19414811
[TBL] [Abstract][Full Text] [Related]
2. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
[TBL] [Abstract][Full Text] [Related]
3. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
[TBL] [Abstract][Full Text] [Related]
4. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
Marigo I; Dolcetti L; Serafini P; Zanovello P; Bronte V
Immunol Rev; 2008 Apr; 222():162-79. PubMed ID: 18364001
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression.
Roth F; De La Fuente AC; Vella JL; Zoso A; Inverardi L; Serafini P
Cancer Res; 2012 Mar; 72(6):1373-83. PubMed ID: 22282665
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cell heterogeneity and subset definition.
Peranzoni E; Zilio S; Marigo I; Dolcetti L; Zanovello P; Mandruzzato S; Bronte V
Curr Opin Immunol; 2010 Apr; 22(2):238-44. PubMed ID: 20171075
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY
J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.
Greifenberg V; Ribechini E; Rössner S; Lutz MB
Eur J Immunol; 2009 Oct; 39(10):2865-76. PubMed ID: 19637228
[TBL] [Abstract][Full Text] [Related]
9. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.
Ochoa AC; Zea AH; Hernandez C; Rodriguez PC
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):721s-726s. PubMed ID: 17255300
[TBL] [Abstract][Full Text] [Related]
10. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.
Zea AH; Rodriguez PC; Atkins MB; Hernandez C; Signoretti S; Zabaleta J; McDermott D; Quiceno D; Youmans A; O'Neill A; Mier J; Ochoa AC
Cancer Res; 2005 Apr; 65(8):3044-8. PubMed ID: 15833831
[TBL] [Abstract][Full Text] [Related]
11. Analysis of splenic Gr-1int immature myeloid cells in tumor-bearing mice.
Yamamoto Y; Ishigaki H; Ishida H; Itoh Y; Noda Y; Ogasawara K
Microbiol Immunol; 2008 Jan; 52(1):47-53. PubMed ID: 18352913
[TBL] [Abstract][Full Text] [Related]
12. Myeloid derived suppressor cells and their role in tolerance induction in cancer.
Fujimura T; Mahnke K; Enk AH
J Dermatol Sci; 2010 Jul; 59(1):1-6. PubMed ID: 20570112
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics.
Umemura N; Saio M; Suwa T; Kitoh Y; Bai J; Nonaka K; Ouyang GF; Okada M; Balazs M; Adany R; Shibata T; Takami T
J Leukoc Biol; 2008 May; 83(5):1136-44. PubMed ID: 18285406
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells.
Varga G; Ehrchen J; Tsianakas A; Tenbrock K; Rattenholl A; Seeliger S; Mack M; Roth J; Sunderkoetter C
J Leukoc Biol; 2008 Sep; 84(3):644-50. PubMed ID: 18611985
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells.
Nefedova Y; Fishman M; Sherman S; Wang X; Beg AA; Gabrilovich DI
Cancer Res; 2007 Nov; 67(22):11021-8. PubMed ID: 18006848
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory cell infiltration of tumors: Jekyll or Hyde.
Talmadge JE; Donkor M; Scholar E
Cancer Metastasis Rev; 2007 Dec; 26(3-4):373-400. PubMed ID: 17717638
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
Sinha P; Clements VK; Fulton AM; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4507-13. PubMed ID: 17483367
[TBL] [Abstract][Full Text] [Related]
18. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
Donkor MK; Lahue E; Hoke TA; Shafer LR; Coskun U; Solheim JC; Gulen D; Bishay J; Talmadge JE
Int Immunopharmacol; 2009 Jul; 9(7-8):937-48. PubMed ID: 19362167
[TBL] [Abstract][Full Text] [Related]
19. Antigen specificity of immune suppression by myeloid-derived suppressor cells.
Solito S; Bronte V; Mandruzzato S
J Leukoc Biol; 2011 Jul; 90(1):31-6. PubMed ID: 21486906
[TBL] [Abstract][Full Text] [Related]
20. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy.
Talmadge JE
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5243-8. PubMed ID: 17875751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
